Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Amgen Inc.

Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Multiple Myeloma

Release Date: February 28, 2018
Expiration Date: February 28, 2019
Media: Internet - based


Activity Overview

This online activity is designed to update physicians on data presented at a major oncology meeting, held in Atlanta, GA, in December 2017, to facilitate critical assessment and, when appropriate, clinical integration of new evidence. The activity reviews 4 abstracts selected by the program faculty, Shaji Kumar, MD, as the most clinically relevant from the meeting. For each abstract, a short summary of key clinical data is accompanied by faculty commentary that provides insight into how new data fit into the current field, and how clinicians can apply these findings to their clinical practice to improve patient care. Interactive questions are interspersed throughout the activity to enable engagement, learning, and self-assessment.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen Inc.

CME Activity Table of Contents

  • Updated Efficacy and Safety From the Phase III Study of Daratumumab, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
  • Updated Results on the Use of CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
  • Final Overall Survival From a Phase III Study of Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
  • An Integrated Analysis From Multiple Phase I/II Studies of Ixazomib in Patients With Newly Diagnosed Multiple Myeloma

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists who treat patients with multiple myeloma. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with multiple myeloma are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Detail the design, efficacy, and safety endpoints of ongoing and recently completed clinical trials in patients with multiple myeloma
  • Elaborate on key efficacy and safety results concerning the use of novel strategies in patients with multiple myeloma and how to incorporate them into practice
  • Place presented clinical trial evidence in the context of evolving treatment paradigms and strategies in the management of patients with multiple myeloma

Faculty, Staff, and Planners' Disclosures


Shaji Kumar, MD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, MN

Disclosure:Consultant: Amgen, Astellas, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences Inc., Vaniam Group LLC, AbbVie, Alexion; Research Support: Kite, Regeneron, Acerta; Consultant/Research Support: Gilead, Pharmacyclics, TG Therapeutics, Pfizer, Sunesis.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By